Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a set of step-by step evidence-based, consensus-driven recommendations to ensure that patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patient’s preferences when applying the guidelines to ensure optimal care for the individual. The multidisciplinary team discusses how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines® to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the guidelines might be best applied.
NCCN will offer a series of twelve multidisciplinary case-based webinars on the management of patients with various cancer types, including: breast cancer, chronic lymphocytic leukemia, endometrial cancer, kidney cancer, lung cancer, multiple myeloma, neuroendocrine tumors, non-melanoma skin cancer, ovarian cancer, pediatric acute lymphoblastic leukemia, prostate cancer, and rectal cancer.
This program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with cancer.
The goal of this project is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to:
- Apply the current standards of oncology care and NCCN Clinical Practice Guidelines in Oncology to optimize the management of patients with various cancer types.
- Review new, emerging, and novel therapeutic agents and treatment strategies and incorporate these into the management of patients with cancer.
- Communicate the importance of a multidisciplinary approach and improve the collaborative performance of the interprofessional oncology care team in the management of patients with cancer.
New Treatments for Metastatic Lung Cancer
Thursday, February 27, 2020 • 2:30 – 3:30 PM EST
Sandip P. Patel, MD, and Grace Y. Lin, MD, PhD, UC San Diego Moores Cancer Center
Strategies for Management of Transplant-Ineligible Patients
Monday, March 2, 2020 • 1:00 – 2:00 PM EST
Noopur Raje, MD, and Cindy C. Harrington, NP, Massachusetts General Hospital Cancer Center
ALL WEBINAR TIMES ARE POSTED AS EASTERN DAYLIGHT TIME (EDT) (UTC/GMT -4:00) OR EASTERN STANDARD TIME (EST) (UTC/GMT -5:00).
Access to participate in selected sessions is through the NCCN WebEx Site on the day of each scheduled program.
The most recent recorded webcasts from this series are listed below. You can also view recorded webcasts from the 2018-2019 Monthly Oncology Tumor Board Series.
- Prostate Cancer - The Emerging Role of Tumor and Germline Genetic Testing and the Treatment of Advanced Disease (held on June 24, 2019, and presented by Sandy Srinivas, MD, and Sumit A. Shah, MD, MPH, Stanford Cancer Institute)
- Breast Cancer - Management of Metastatic Triple Negative Disease (held on Tuesday, July 30, 2019, and presented by Melinda L. Telli, MD, and Jessica Foran, MSN, WHNP-BC, ANP-BC, Stanford Cancer Institute)
- Pediatric Acute Lymphoblastic Leukemia (ALL) - Emerging Strategies for Pediatric ALL Management (held on August 22, 2019, and presented by Patrick A. Brown, MD, and Sarah Getman Poggi, RN, MSN, CPNP-AC, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins)
- Advanced Renal Cell Carcinoma Systemic Treatment Selection (held on October 16, 2019, and presented by Elizabeth R. Plimack, MD, MS, and Colleen H. Tetzlaff, MHS, PA-C, Fox Chase Cancer Center)
- Optimizing the Care of Endometrial Cancer - Minimally Invasive Surgery and Systemic Therapy (held on October 21, 2019, and presented by Andrea Mariani, MD, and Nicole Bush, APRN, CNP, Mayo Clinic Cancer Center)
- Updates in the Management of Merkel Cell Carcinoma, with a Focus on Systemic Therapy (held on November 13, 2019, and presented by Paul Nghiem, MD, PhD, University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, and Coley J. Doolittle-Amieva, PA-C, Seattle Cancer Care Alliance/University of Washington)
- Management of Advanced Neuroendocrine Tumors (held on Thursday, December 12, 2019, and presented by Jonathan R. Stosberg, MD and Ghassan El-Haddad, MD, Moffitt Cancer Center)
- Emerging Treatment Options in Advanced Ovarian Cancer (held on Tuesday, January 21, 2020, and presented by Ronald D. Alvarez, MD, MBA, Vanderbilt-Ingram Cancer Center, and Joyce Liu, MD, Dana-Farber/Brigham and Women's Cancer Center)
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Full disclosure of faculty relationships will be made prior to the activity.
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. NCCN will also seek approval for case manager clock hours. Complete accreditation information is provided before each individual educational activity.
Please refer to the Schedule tab for dates and times. Check the webinars you would like to attend and click Enroll.
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing